Facing the world, expanding openness, breaking conventions, and innovating breakthroughs. As a pioneer in innovative development, Shanghai Pudong has always carried the mission of "making every effort to strengthen the innovation engine and create a new highland of independent innovation". Entering Pudong, from breakthroughs in basic research at the forefront of world technology, to the construction of an international science and technology innovation center for people's lives and health, and to the flourishing development of global enterprise innovation, each story of innovative development depicts a vivid scene of China's innovation going global. From 0 to 1, China's original technology enhances the world's basic research, which is the source of the entire scientific system. In Zhangjiang, Pudong, a cutting-edge life science field of gene editing, an original technology originating from China is rewriting the fate of hundreds of thousands of genetic disease patients worldwide. Our technology is focused on precise correction of the 3 billion nucleotides in the human body, rather than reconstruction after destruction. ”The CEO of Zhengxu Biotechnology, Mou Xiaodun, introduced it as follows. This technology, called Variant Base Editor (tBE), was incubated by ShanghaiTech University and is the world's first Chinese original base editing tool to receive overseas patent authorization. Traditional gene editing techniques are like "molecular scissors" that modify genes by cutting DNA double strands, but they can easily cause cell death and chromosome rearrangement. Chen Jia, founder of Zhengxu Biology and professor at ShanghaiTech University, has taken a different approach by transforming "molecular scissors" into "gene correction pens", achieving a leap from "open chest" to "minimally invasive". Since 2019, this technology has been granted patents in China, the United States, Japan, Russia and other countries and regions, marking China's independent voice in the forefront of gene editing. In the outline of the 15th Five Year Plan, biomedicine is listed alongside integrated circuits, aerospace, and low altitude economy, and included in the layout of emerging pillar industries. Currently, Zhengxu Biotechnology is applying for the first base edited drug. The synergy of scientific research system, transformation system, and regulatory system constitutes the supporting system for China's breakthrough in original technology. "Mou Xiaodun is full of confidence in the future. During the clinical trial phase, Elsa, a 4-year-old girl from Pakistan suffering from thalassemia, became the first overseas child to benefit from this technology. At the discharge ceremony, Elsa's father presented flowers to the Chinese medical team, thanking Chinese technology for "allowing children to see the future again". Our dream is to bring Chinese products and establish international standards. ”Mou Xiaodun said that Chinese innovation not only solves its own problems, but also has the ability to benefit the world. To build a world-class science and technology innovation center from point to surface, we entered Zhangjiang Pharmaceutical Valley in Pudong. There are not only international pharmaceutical giants such as Roche, Novartis, Johnson and Johnson, but also a batch of local innovation forces emerging from the laboratory, forming a dynamic pattern of "large enterprises stand tall and small enterprises spread out", and creating a complete ecological closed-loop from basic research to industrialization. Zhangjiang Pharmaceutical Valley is now the innovation leading core area for the development of Shanghai's biopharmaceutical industry, and an important main battlefield for building a science and technology innovation center. ”Introduction by Liu Gang, General Manager of Shanghai Zhangjiang Medicinal Valley Public Service Platform Co., Ltd. In Zhangjiang Medicine Valley, innovative products that are globally first, first in China, and clinically first are continuously emerging. At present, Zhangjiang Pharmaceutical Valley has been approved for 32 domestically produced Class I new drugs and 49 innovative medical device products. Innovative drugs continue to 'go global', with 40 overseas authorized transactions in Zhangjiang Pharmaceutical Valley by 2025, accounting for 22% of the country's total, with an annual growth rate of 11%. The high degree of industrial agglomeration and complete industrial chain are the "magic weapons" for Zhangjiang Pharmaceutical Valley to sustain innovation. Liu Gang said, "Our industrial ecosystem covers storage, research and development, manufacturing, application, equipment, etc., providing full chain services for enterprises from incubation and cultivation to rapid development. Currently, Zhangjiang Pharmaceutical Valley is actively laying out many new fields and tracks such as cell gene therapy, brain computer interface, AI pharmaceuticals, isotope drugs, etc., leading the country. Leading enterprises amplify the cluster effect, relying on the innovative source capabilities of universities such as Fudan and ShanghaiTech, and assisting in connecting with clinical research and regulatory departments through technical and financial support to promote the rapid growth of new technologies. ”Lin Jianfei, Director of the Biomedical Department of Pudong New Area Science and Technology Commission, said. Starting from the listing authorization holder system, to compressing the approval time limit for clinical trial applications of innovative drugs to 30 working days, and then to the three-level linkage mechanism of the National Medical Products Administration, the Municipal Medical Products Administration, and Pudong New Area, Pudong has been leading the way in promoting industrial innovation through institutional innovation. In Pudong, the Open Innovation Center for Large Enterprises has formed a collaborative innovation ecosystem of "empowering small enterprises with large enterprises". The "Regulatory Science Salon" discusses breakthroughs around bottleneck issues, the Synthetic Biology Innovation Center explores new incubation mechanisms in emerging fields, and the Common Service Platform helps enterprises reduce costs and increase efficiency, and build an innovation ecosystem. Innovation is about breaking through bottlenecks. We need to use Pudong as a testing ground for institutional innovation, open up space for industrial innovation, and inject momentum into building a world-class science and technology innovation center. ”Liu Gang said. From following to leading, Qinglang Intelligent actively integrates into global competition in Pudong. The reporter witnessed the transformation of Chinese enterprises from "following" to "leading". This enterprise, founded in 2010, mainly provides service robot products and complete solutions. At present, the sales proportion of domestic and overseas markets of the enterprise is roughly equal. The overseas market mainly focuses on countries and regions with high labor costs, such as North America, Europe, South Korea, and so on. It should be said that in order for Chinese technology products to enter the markets of developed countries, they had to go through some challenges in the past. ”Li Tong, founder and CEO of Qinglang Intelligent, admitted, "We spent 5 years on global layout." Chen Qian from Qinglang's marketing department summarized the changes in the competitiveness of Chinese robot products in one sentence: "Previously, Chinese products achieved 80% performance at 50% price; now they achieve 150% performance at 80% price." Nowadays, in terms of service robots, domestic enterprises have entered the world's top tier with rich application scenarios and massive data. Qinglang Intelligent has also become an important supplier of global commercial service robots. In addition, Qinglang has also participated in the development of 2 international standards, 5 national standards, and 20 group standards. Among them, the UL service robot standard that participated in the development in North America has been officially implemented. This is a reflection of China's technological strength and a powerful proof of the rising international status of China's emerging industries. ”Li Tong said. Li Tong is full of confidence in the future industry of embodied intelligence. In the field of embodied intelligence, China is far ahead globally. "He shared a story:" The Japan Broadcasting Corporation Television once organized the Sino Japanese Robot Challenge, and under the topic set by the other party, we achieved an absolute victory. We have gained recognition from global customers through excellent product performance. Currently, facing the impact and challenges of unilateralism and protectionism in a few countries, Qinglang has shown great resilience in overseas markets. In 2025, our overseas revenue will continue to grow because the world has seen the strong strength of Chinese technology. "Regarding China's technological strength, Han Chen, President of ABB Robotics China, explained from the perspective of the industrial chain:" A large number of parts procurement in the robotics industry needs to be completed in China, including castings, cables, sheet metal, and components, none of which can bypass the Chinese industrial chain. "Han Chen is also confident in the development of embodied intelligence in China. He said that China is at the forefront of industry standard setting in the world and may play a global leading role in the future. Breakthrough in openness and grow in competition. From biopharmaceuticals to embodied intelligence, from primitive innovation to industrial applications, from leveraging the role of enterprise innovation as the main body to building a world-class innovation ecosystem, China is accelerating to become an important pole of global innovation. (Looking into the New Era)